Syed Faizaan, Trifa Mehdi, Uffman Joshua C, Tumin Dmitry, Tobias Joseph D
Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio.
Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Pediatr Qual Saf. 2018 Oct 9;3(5):e113. doi: 10.1097/pq9.0000000000000113. eCollection 2018 Sep-Oct.
Anesthesiologists use sugammadex to reverse neuromuscular blockade (NMB) produced by rocuronium and vecuronium. Its mechanism involves encapsulation of the neuromuscular blocking agent. Sugammadex dosing is based on the depth of NMB, assessed by measuring the train-of-four (TOF).
We retrospectively reviewed procedures under general anesthesia in patients older than 1 year of age if they included sugammadex reversal of rocuronium-induced NMB. Documentation of TOF monitoring before and after reversal was noted, along with the dose of sugammadex administered. TOF was considered correctly documented if the anesthesia provider recorded the number of twitches before and after NMB reversal, or if they recorded 4 twitches before NMB reversal. We defined appropriate sugammadex dosing if it was within 10% of the recommended dose for the depth of NMB. We repeated this review after staff education and creating a reminder in the electronic health record system.
We included 100 patients in the preintervention analysis, of whom 30% had correct TOF documentation. Among patients with TOF assessment before sugammadex administration, the dose was appropriate in 34 of 40 cases. In the postintervention analysis, we reviewed 75 cases and found that correct documentation improved to 45% ( = 0.024). Among postintervention cases with TOF documented before sugammadex administration, sugammadex dosing was appropriate in 62 patients.
Documentation of TOF was low (30%) before intervention and improved to only 45% after the interventions, suggesting that additional interventions are needed. Even before the intervention, with or without TOF documentation, the dose of sugammadex was generally consistent with recommendations.
麻醉医生使用舒更葡糖来逆转罗库溴铵和维库溴铵所致的神经肌肉阻滞(NMB)。其作用机制包括包裹神经肌肉阻滞剂。舒更葡糖的给药剂量基于通过四个成串刺激(TOF)测量评估的NMB深度。
我们回顾性分析了年龄大于1岁、全麻下使用舒更葡糖逆转罗库溴铵诱导的NMB的手术。记录逆转前后TOF监测的情况以及舒更葡糖的给药剂量。如果麻醉医生记录了NMB逆转前后的颤搐次数,或者记录了NMB逆转前4次颤搐,则认为TOF记录正确。如果舒更葡糖的给药剂量在NMB深度推荐剂量的10%范围内,我们定义为给药剂量合适。在员工培训并在电子健康记录系统中设置提醒后,我们重复了此项回顾分析。
在干预前分析中纳入了100例患者,其中30%有正确的TOF记录。在舒更葡糖给药前进行TOF评估的患者中,40例中有34例剂量合适。在干预后分析中,我们回顾了75例病例,发现正确记录提高到了45%(P = 0.024)。在干预后舒更葡糖给药前记录了TOF的病例中,62例患者的舒更葡糖给药剂量合适。
干预前TOF记录率较低(30%),干预后仅提高到45%,这表明需要采取更多的干预措施。即使在干预前,无论有无TOF记录,舒更葡糖的剂量总体上与推荐剂量一致。